MedTrace Logo

Effects of Fimasartan on Insulin Secretion in Type 2 Diabetic Patients

NCT02312375 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2017-04-28

No results posted yet for this study

Summary

This study was designed to evaluate the effect of ARB in improving insulin secretion in patients with type 2 diabetes. The investigators also aimed to evaluate if there are potential synergisms between ARB and DPP4 inhibitors in improving insulin secretion and urinary albumin secretion in diabetic patients.

Conditions

Interventions

DRUG

Fimasartan

16 weeks of fimasartan vs. amlodipine followed by 2 weeks of wash-out period, then crossover

DRUG

Amlodipine

16 weeks of fimasartan vs. amlodipine followed by 2 weeks of wash-out period, then crossover

Sponsors & Collaborators

  • Seoul National University Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2016-12-31
Completion
2017-03-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02312375 on ClinicalTrials.gov